Loading
A phase 2/3 trial of Docetaxel in gastric & gastro-oesophageal junction cancer, run by Shanghai JMT-Bio Inc., now recruiting.
KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy is a phase 2/3 interventional study registered as NCT05427383 by Shanghai JMT-Bio Inc., with 286 participants planned, started 2022-04-07 and due to reach its primary completion in 2025-11. Interventions recorded: KN026/Placbo Injection, Paclitaxel Injection, Docetaxel Injection and Irinotecan Injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares CSPC Pharmaceutical Group, Docetaxel, Gastric & gastro-oesophageal junction cancer, Cytotoxic chemotherapy and the tag pipeline.
Shares CSPC Pharmaceutical Group, Docetaxel, Gastric & gastro-oesophageal junction cancer, Cytotoxic chemotherapy and the tag pipeline.
Shares Docetaxel, Gastric & gastro-oesophageal junction cancer, Cytotoxic chemotherapy and the tag pipeline.
Shares HER2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares HER2-positive gastric cancer, Docetaxel, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Docetaxel, Cytotoxic chemotherapy and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.
Shares Docetaxel, Cytotoxic chemotherapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/